We performed 2 case-control association studies whereby we looked at the role of genetic polymorphisms in ACE, eNOS and beta2-adrenergic receptors with risk of hypertension. We used historic controls who were previously recruited for a separate study (see the role of CYP2C9 and VKORC1 genetic polymorphisms on anticoagulation).
Manuscript 1: Akra-Ismail M, Makki RF, Chmaisse HN, Kazma A, Zgheib NK. Association between angiotensin-converting enzyme insertion/deletion genetic polymorphism and hypertension in a sample of Lebanese patients. Genet Test Mol Biomarkers. 2010 Dec;14(6):787-92 (PMID: 20939740 ).
Manuscript 2: Soudani NY, Fakhoury RM, Kaissi SS, Zgheib NK. The role of genetic polymorphisms in endothelial nitric oxide synthase and beta2-adrenergic receptors with risk of hypertension in a sample of Lebanese people. Saudi Med J. 2014 Mar;35(3):255-60 (PMID: 24623205).
See the role of CYP2C9 and VKORC1 genetic polymorphisms on anticoagulation study.
See the role of CYP2C9 and VKORC1 genetic polymorphisms on anticoagulation study.
See the role of CYP2C9 and VKORC1 genetic polymorphisms on anticoagulation study.
See the role of CYP2C9 and VKORC1 genetic polymorphisms on anticoagulation study.